Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 2/20 | 0.40 |
| ▸ | FEN1 | P39748 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3760158 | 0.79 | IRAK4 (0.49) | ALOX5APFEN1SOS2IRAK4CTSK | |
| SCHEMBL23355870 | 0.78 | GABRA5 (0.36) | ALOX5APFEN1KCNH2SOS2IRAK4 | |
| SCHEMBL17067514 | 0.78 | ALOX5AP (0.36) | ALOX5APFEN1KCNH2SOS2IRAK4 | |
| SCHEMBL14075038 | 0.77 | ALOX5AP (0.35) | ALOX5APFEN1KCNH2SOS2IRAK4 | |
| SCHEMBL929565 | 0.77 | IDH1 (0.38) | ALOX5APFEN1KCNH2SOS2CTSK | |
| Hydrochloric Acid SCHEMBL9296794 | 0.77 | IRAK4 (0.48) | ALOX5APFEN1SOS2IRAK4CTSK | |
| SCHEMBL27835923 | 0.76 | HRH1 (0.42) | ALOX5APFEN1KCNH2SOS2IRAK4 | |
| SCHEMBL23796077 | 0.75 | ALOX5AP (0.48) | ALOX5APFEN1KCNH2CTSKGABRA5 | |
| SCHEMBL9298287 | 0.75 | ALDH1A1 (0.42) | ALOX5APFEN1SOS2SRC | |
| SCHEMBL863712 | 0.75 | KCNH2 (0.50) | ALOX5APFEN1KCNH2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190000832-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | Selder Pharma Inc. (US) | 2019-01-03 | — | — | US | disclosed |
| US-10016410-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016410-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170189390-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | SELDAR PHARMA INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170189390-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | SELDAR PHARMA INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-9526719-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9526719-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150359787-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | SELDAR PHARMA INC. (US) | 2015-12-17 | — | — | US | disclosed |
| US-9150541-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150541-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140058100-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | SELDAR PHARMA INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-8486970-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486970-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20100227866-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20100227866-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-09 | — | — | US | disclosed |
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1830858-A2 | 3, 6-BICYCLOLIDES | Enanta Pharmaceuticals, Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20060142214-A1 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
| WO-2006063039-A2 | 3, 6-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189390-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | BRS3, BDKRB2, NTSR2 | ALOX5AP 3341/4885FEN1 4718/4885KCNH2 1026/4885 |
| US-20150359787-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | BRS3, BDKRB2, NTSR2 | ALOX5AP 3341/4885FEN1 4718/4885KCNH2 1026/4885 |
| US-10016410-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | BRS3, BDKRB2, NTSR2 | ALOX5AP 3341/4885FEN1 4718/4885KCNH2 1026/4885 |
| US-20100227866-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | BRS3, BDKRB2, NTSR2 | ALOX5AP 3051/4885FEN1 4759/4885KCNH2 975/4885 |
| US-20060142214-A1 | 3,6-bicyclolides | ABCB11, CYP2B6, CYP3A7 | ALOX5AP 847/4885FEN1 3253/4885KCNH2 2968/4885 |
| US-20140058100-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | BRS3, BDKRB2, NTSR2 | ALOX5AP 3341/4885FEN1 4718/4885KCNH2 1026/4885 |
| US-20190000832-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | BRS3, BDKRB2, NTSR2 | ALOX5AP 3341/4885FEN1 4718/4885KCNH2 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.